SCHEMBL11029790

SCHEMBL11029790

CN1CCN(c2ccc(Nc3cc(Cc4cccc(C(F)(F)F)c4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 2/20 0.52
▸ PTK2 Q05397 1/20 0.52
▸ STAT6 P42226 2/20 0.50
▸ CTSC P53634 2/20 0.49
▸ GALR3 O60755 1/20 0.49
▸ LCK P06239 4/20 0.48
▸ KDR P35968 4/20 0.48
▸ MAPK14 Q16539 4/20 0.48
▸ TEK Q02763 2/20 0.48
▸ FYN P06241 2/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ CSF1R P07333 1/20 0.48
▸ LYN P07948 1/20 0.48
▸ SRC P12931 1/20 0.48
▸ MAPK9 P45984 1/20 0.48
▸ JAK3 P52333 1/20 0.48
▸ MET P08581 1/20 0.47
▸ SLC2A1 P11166 1/20 0.46
▸ BTK Q06187 2/20 0.46
▸ HRH4 Q9H3N8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11028029 0.89 CDK4 (0.53) MAPKAPK2PTK2STAT6FYNCSF1R
SCHEMBL11030519 0.88 MAPKAPK2 (0.49) MAPKAPK2PTK2STAT6JAK3SLC2A1
SCHEMBL11025081 0.87 STAT6 (0.55) MAPKAPK2PTK2STAT6CSF1RSLC2A1
SCHEMBL11029481 0.87 SLC2A1 (0.52) MAPKAPK2PTK2STAT6LCKMAPK14
SCHEMBL11031933 0.85 MAPKAPK2 (0.51) MAPKAPK2PTK2STAT6CSF1RSLC2A1
SCHEMBL11027579 0.84 SLC2A1 (0.49) MAPKAPK2PTK2STAT6JAK3SLC2A1
SCHEMBL11027886 0.84 SLC2A1 (0.47) MAPKAPK2PTK2STAT6CSF1RJAK3
SCHEMBL11028773 0.84 MAPKAPK2 (0.50) MAPKAPK2PTK2STAT6CSF1RJAK3
SCHEMBL11027435 0.84 STAT6 (0.49) MAPKAPK2PTK2STAT6CSF1RSLC2A1
SCHEMBL11029564 0.83 TNIK (0.52) PTK2STAT6CSF1RSLC2A1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 MAPKAPK2 115/4885PTK2 290/4885STAT6 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback